TD Cowen has lowered Eli Lilly’s price target from $1,050 to $960, but maintained a Buy rating, citing solid long-term ...

Erste Group has downgraded Eli Lilly from a buy to a hold rating due to concerns about its earnings forecast. Despite 36.38% ...

Now, let's return to our question: Should you invest $1,000 in Lilly right now? The shares are trading for 34 times forward ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

Eli Lilly (NYSE: LLY) has been a growth beast over the years and is now easily the most valuable healthcare company in the ...

Financial Stability: Eli Lilly's balance sheet is more robust, with debt making up only 4% of equity, considerably less than ...

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, USA, with products marketed in 120 countries. Eli Lilly Austria, Switzerland, Germany is the company’s third ...

Winkler said her company would like to help New Palestine leaders be more intentional with their branding. Winkler said the ...

Employers have the opportunity to lead by example: to stop treating obesity as invisible and start addressing it as the ...

Eli Lilly and Company (NYSE:LLY) recently announced that Australia’s Therapeutic Goods Administration (TGA) has approved Kisunla (donanemab) for marketing. The drug, administered via intravenous ...